Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Most cited

Page Path
HOME > Browse Articles > Most cited
85 Most cited
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles

From articles published in Journal of Movement Disorders during the past two years (2020 ~ ).

Review Articles
COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson’s Disease Patient Care
Roongroj Bhidayasiri, Sasivimol Virameteekul, Jong-Min Kim, Pramod Kr. Pal, Sun-Ju Chung
J Mov Disord. 2020;13(2):105-114.   Published online April 30, 2020
DOI: https://doi.org/10.14802/jmd.20042
  • 16,964 View
  • 741 Download
  • 42 Citations
AbstractAbstract PDF
While many infectious disorders are unknown to most neurologists, COVID-19 is very different. It has impacted neurologists and other health care workers, not only in our professional lives but also through the fear and panic within our own families, colleagues, patients and their families, and even in the wider public. COVID-19 affects all sorts of individuals, but the elderly with underlying chronic conditions are particularly at risk of severe disease, or even death. Parkinson’s disease (PD) shares a common profile as an age-dependent degenerative disorder, frequently associated with comorbidities, particularly cardiovascular diseases, so PD patients will almost certainly fall into the high-risk group. Therefore, the aim of this review is to explore the risk of COVID-19 in PD based on the susceptibility to severe disease, its impact on PD disease severity, potential long-term sequelae, and difficulties of PD management during this outbreak, where neurologists face various challenges on how we can maintain effective care for PD patients without exposing them, or ourselves, to the risk of infection. It is less than six months since the identification of the original COVID-19 case on New Year’s Eve 2019, so it is still too early to fully understand the natural history of COVID-19 and the evidence on COVID-19-related PD is scant. Though the possibilities presented are speculative, they are theory-based, and supported by prior evidence from other neurotrophic viruses closely related to SARS-CoV-2. Neurologists should be on high alert and vigilant for potential acute and chronic complications when encountering PD patients who are suspected of having COVID-19.

Citations

Citations to this article as recorded by  
  • Doctor Hope; Calming and Comforting Loneliness in Parkinson’s Disease
    Sasivimol Virameteekul, Roongroj Bhidayasiri
    Clinical Parkinsonism & Related Disorders.2022; 6: 100131.     CrossRef
  • Neurological toll of COVID-19
    Shivam Bhola, Jhillika Trisal, Vikram Thakur, Parneet Kaur, Saurabh Kulshrestha, Shashi Kant Bhatia, Pradeep Kumar
    Neurological Sciences.2022; 43(4): 2171.     CrossRef
  • Resilience and Trauma among Patients with Parkinson’s Disease during the COVID-19 Pandemic
    Roberto Erro, Sofia Cuoco, Emanuele Nigro, Raffaele Ragone, Paolo Barone
    Journal of Movement Disorders.2022; 15(1): 77.     CrossRef
  • Implication of Covid-19 on Neurological Complications with Specific Emphasis on Alzheimer’s and Parkinson’s Disease
    Ankita Sood, Ravi Goyal, Harshdeep Singh, Tapan Behl, Sandeep Arora, Balraj Saini, Rajwinder Kaur
    CNS & Neurological Disorders - Drug Targets.2022; 21(3): 235.     CrossRef
  • The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design
    Konrad Rejdak, Piotr Fiedor, Robert Bonek, Aleksander Goch, Agnieszka Gala-Błądzińska, Waldemar Chełstowski, Jacek Łukasiak, Sławomir Kiciak, Piotr Dąbrowski, Mateusz Dec, Zbigniew J. Król, Ewa Papuć, Adriana Zasybska, Agnieszka Segiet, Paweł Grieb
    Contemporary Clinical Trials.2022; 116: 106755.     CrossRef
  • Neuropathological Aspects of SARS-CoV-2 Infection: Significance for Both Alzheimer’s and Parkinson’s Disease
    Jaime Silva, Felipe Patricio, Aleidy Patricio-Martínez, Gerardo Santos-López, Lilia Cedillo, Yousef Tizabi, Ilhuicamina Daniel Limón
    Frontiers in Neuroscience.2022;[Epub]     CrossRef
  • Online dance classes during the Covid-19 pandemic: new challenges and teaching strategies for the ‘Dance & Parkinson’s at home’ project
    Marcela Dos Santos Delabary, Isadora Loch Sbeghen, Mariana Wolffenbuttel, Djefri Ramon Pereira, Aline Nogueira Haas
    Research in Dance Education.2022; : 1.     CrossRef
  • Impact of the COVID-19 Pandemic on Chronic Neurological Disorders: Focus on Patients with Dementia
    Maria Antonietta Barbieri, Gianluca Bagnato, Carmelo Ioppolo, Antonio Giovanni Versace, Natasha Irrera
    CNS & Neurological Disorders - Drug Targets.2022; 21(10): 1017.     CrossRef
  • COVID-19 and Parkinson’s disease: a systematic review and meta-analysis
    Maryam Afraie, Ghobad Moradi, Pardis Mohammadzedeh, Mobin Azami, Sevda Riyahifar, Yousef Moradi
    Acta Neurologica Belgica.2022;[Epub]     CrossRef
  • Attitudes toward telemedicine of patients with Parkinson’s disease during the COVID‐19 pandemic
    Kanako Kurihara, Koichi Nagaki, Kotoe Inoue, Sumiko Yamamoto, Takayasu Mishima, Shinsuke Fujioka, Shinji Ouma, Yoshio Tsuboi
    Neurology and Clinical Neuroscience.2021; 9(1): 77.     CrossRef
  • Risk of Hospitalization and Death for COVID ‐19 in People with Parkinson's Disease or Parkinsonism
    Luca Vignatelli, Corrado Zenesini, Laura M.B. Belotti, Elisa Baldin, Giuseppe Bonavina, Giovanna Calandra‐Buonaura, Pietro Cortelli, Carlo Descovich, Giovanni Fabbri, Giulia Giannini, Maria Guarino, Roberta Pantieri, Giuseppe Samoggia, Cesa Scaglione, Sus
    Movement Disorders.2021; 36(1): 1.     CrossRef
  • Impact of COVID-19 in the Mental Health in Elderly: Psychological and Biological Updates
    Roberta Eduarda Grolli, Maiqueli Eduarda Dama Mingoti, Amanda Gollo Bertollo, Adriana Remião Luzardo, João Quevedo, Gislaine Zilli Réus, Zuleide Maria Ignácio
    Molecular Neurobiology.2021; 58(5): 1905.     CrossRef
  • COVID-19: Implications for Sudden Death in Parkinson’s Disease
    Ana Claudia Fiorini, Marcelo Cunio Machado Fonseca, Carla Alessandra Scorza, Josef Finsterer, Antônio Márcio Rodrigues, Antônio-Carlos Guimarães de Almeida, Fulvio Alexandre Scorza
    Journal of Movement Disorders.2021; 14(1): 78.     CrossRef
  • Impact and Challenges of the COVID-19 Pandemic on Patients Requiring Botulinum Toxin A Treatment
    Azalea Tenerife Pajo, Adrian Isidoro Espiritu, Roland Dominic Go Jamora
    Journal of Movement Disorders.2021; 14(1): 29.     CrossRef
  • COVID-19 in age-related neurodegenerative diseases: is there a role for vitamin D3 as a possible therapeutic strategy?
    Milena de Barros Viana, Bárbara dos Anjos Rosário, Maria de Fátima Santana de Nazaré, Débora Estadella, Daniel Araki Ribeiro, Glauce Socorro de Barros Viana
    Reviews in the Neurosciences.2021; 32(2): 235.     CrossRef
  • How COVID-19 will boost remote exercise-based treatment in Parkinson’s disease: a narrative review
    Agnes Langer, Lucia Gassner, Anna Flotz, Sebastian Hasenauer, Jakob Gruber, Laurenz Wizany, Rochus Pokan, Walter Maetzler, Heidemarie Zach
    npj Parkinson's Disease.2021;[Epub]     CrossRef
  • Neurological Manifestation of SARS-CoV-2 Induced Inflammation and Possible Therapeutic Strategies Against COVID-19
    Dipak Kumar, Sadaf Jahan, Andleeb Khan, Arif Jamal Siddiqui, Neeru Singh Redhu, Wahajuddin, Johra Khan, Saeed Banwas, Bader Alshehri, Mohammed Alaidarous
    Molecular Neurobiology.2021; 58(7): 3417.     CrossRef
  • Auswirkungen der COVID-19 Pandemie auf die medizinische Versorgung von Patienten mit angeborenen Blutungsneigungen
    Martin Olivieri, Susan Halimeh, Cornelia Wermes, Wolf Hassenpflug, Katharina Holstein, Sylvia von Mackensen
    Das Gesundheitswesen.2021; 83(04): 282.     CrossRef
  • Parkinsonism hyperpyraexia syndrome in Parkinson's disease patients undergoing deep brain stimulation: An indirect consequence of COVID-19 lockdowns
    Onanong Phokaewvarangkul, Sasivimol Virameteekul, Roongroj Bhidayasiri
    Parkinsonism & Related Disorders.2021; 87: 39.     CrossRef
  • Clinical Profiles and Mortality of COVID ‐19 Inpatients with Parkinson's Disease in Germany
    Raphael Scherbaum, Eun Hae Kwon, Daniel Richter, Dirk Bartig, Ralf Gold, Christos Krogias, Lars Tönges
    Movement Disorders.2021; 36(5): 1049.     CrossRef
  • Chronic pain experience and health inequities during the COVID-19 pandemic in Canada: qualitative findings from the chronic pain & COVID-19 pan-Canadian study
    Lise Dassieu, M. Gabrielle Pagé, Anaïs Lacasse, Maude Laflamme, Vickie Perron, Audrée Janelle-Montcalm, Maria Hudspith, Gregg Moor, Kathryn Sutton, James M Thompson, Manon Choinière
    International Journal for Equity in Health.2021;[Epub]     CrossRef
  • The Influence of Coronavirus Disease-2019 (COVID-19) On Parkinson’s Disease: An Updated Systematic Review
    Vikash Jaiswal, Danah Alquraish, Zouina Sarfraz, Azza Sarfraz, Shavy Nagpal, Prakriti Singh Shrestha, Dattatreya Mukherjee, Prathima Guntipalli, Diana F. Sánchez Velazco, Arushee Bhatnagar, Saloni Savani, Elmjedina Halilaj, Samir Ruxmohan, Wilson Cueva
    Journal of Primary Care & Community Health.2021; 12: 215013272110397.     CrossRef
  • Personalized Medicine in Parkinson’s Disease: New Options for Advanced Treatments
    Takayasu Mishima, Shinsuke Fujioka, Takashi Morishita, Tooru Inoue, Yoshio Tsuboi
    Journal of Personalized Medicine.2021; 11(7): 650.     CrossRef
  • Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran
    Mehri Salari, Masoud Etemadifar, Farzad Ashrafi, Davood Ommi, Zahra Aminzade, Sepand Tehrani Fateh
    Parkinsonism & Related Disorders.2021; 89: 90.     CrossRef
  • COVID-19 social distancing: negative effects on people with Parkinson disease and their associations with confidence for self-management
    Galit Yogev-Seligmann, Michal Kafri
    BMC Neurology.2021;[Epub]     CrossRef
  • Covid-19 in Parkinson's Disease treated by drugs or brain stimulation
    M. Salari, M. Etemadifar, A. Zali, Z. Aminzade, I. Navalpotro-Gomez, S. Tehrani Fateh
    Neurología.2021;[Epub]     CrossRef
  • Management of Parkinson’s Disease in the COVID-19 Pandemic and Future Perspectives in the Era of Vaccination
    Yue Hui Lau, Keng Ming Lau, Norlinah Mohamed Ibrahim
    Journal of Movement Disorders.2021; 14(3): 177.     CrossRef
  • Parkinson’s Disease and the COVID-19 Pandemic: A Review Article on the Association between SARS-CoV-2 and α-Synucleinopathy
    Smriti Sinha, Swati Mittal, Rupali Roy
    Journal of Movement Disorders.2021; 14(3): 184.     CrossRef
  • Impact of COVID‐19 on Patient Care, Training, and Research in Movement Disorders in MDS‐AOS Region
    Shweta Prasad, Hrishikesh Kumar, Roongroj Bhidayasiri, Pramod Kumar Pal
    Movement Disorders.2021; 36(11): 2457.     CrossRef
  • Secondary Impact of COVID-19 Pandemic on People with Parkinson’s Disease—Results of a Polish Online Survey
    Karolina Krzysztoń, Beata Mielańczuk-Lubecka, Jakub Stolarski, Anna Poznańska, Katarzyna Kępczyńska, Agata Zdrowowicz, Izabela Domitrz, Jan Kochanowski
    Brain Sciences.2021; 12(1): 26.     CrossRef
  • Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital
    Adalberto STUDART-NETO, Bruno Fukelmann GUEDES, Raphael de Luca e TUMA, Antonio Edvan CAMELO FILHO, Gabriel Taricani KUBOTA, Bruno Diógenes IEPSEN, Gabriela Pantaleão MOREIRA, Júlia Chartouni RODRIGUES, Maíra Medeiros Honorato FERRARI, Rafael Bernhart CAR
    Arquivos de Neuro-Psiquiatria.2020; 78(8): 494.     CrossRef
  • Potential impact and challenges associated with Parkinson’s disease patient care amidst the COVID-19 global pandemic
    Ali Elbeddini, Anthony To, Yasamin Tayefehchamani, Cindy Wen
    Journal of Clinical Movement Disorders.2020;[Epub]     CrossRef
  • COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
    David Sulzer, Angelo Antonini, Valentina Leta, Anna Nordvig, Richard J. Smeyne, James E. Goldman, Osama Al-Dalahmah, Luigi Zecca, Alessandro Sette, Luigi Bubacco, Olimpia Meucci, Elena Moro, Ashley S. Harms, Yaqian Xu, Stanley Fahn, K. Ray Chaudhuri
    npj Parkinson's Disease.2020;[Epub]     CrossRef
  • Impact of Prolonged Lockdown due to COVID-19 in Patients with Parkinson's Disease
    Shweta Prasad, VikramVenkappayya Holla, Koti Neeraja, BharathKumar Surisetti, Nitish Kamble, Ravi Yadav, PramodKumar Pal
    Neurology India.2020; 68(4): 792.     CrossRef
  • The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease
    Ethan G. Brown, Lana M. Chahine, Samuel M. Goldman, Monica Korell, Emerald Mann, Daniel R. Kinel, Vanessa Arnedo, Kenneth L. Marek, Caroline M. Tanner
    Journal of Parkinson's Disease.2020; 10(4): 1365.     CrossRef
  • Impact of COVID‐19 pandemic on mental health of patients with inherited bleeding disorders in Germany
    Sylvia Mackensen, Susan Halimeh, Manuela Siebert, Cornelia Wermes, Wolf Hassenpflug, Katharina Holstein, Martin Olivieri
    Haemophilia.2020;[Epub]     CrossRef
  • Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross‐Sectional Survey of 568 Spanish Patients
    Diego Santos‐García, Mila Oreiro, Patricia Pérez, Gemma Fanjul, Jose Manuel Paz González, María José Feal Painceiras, Carlos Cores Bartolomé, Lorena Valdés Aymerich, Carlos García Sancho, Maria del Mar Castellanos Rodrigo
    Movement Disorders.2020; 35(10): 1712.     CrossRef
  • The Impact of COVID ‐19 on Access to Parkinson's Disease Medication
    Julia Ling‐Yu Cheong, Zhao Hang Keith Goh, Connie Marras, Caroline M. Tanner, Meike Kasten, Alastair J. Noyce
    Movement Disorders.2020; 35(12): 2129.     CrossRef
  • Deep Brain Stimulation Battery Exhaustion during the COVID-19 Pandemic: Crisis within a Crisis
    Vikram Venkappayya Holla, Koti Neeraja, Bharath Kumar Surisetti, Shweta Prasad, Nitish Kamble, Dwarakanath Srinivas, Ravi Yadav, Pramod Kumar Pal
    Journal of Movement Disorders.2020; 13(3): 218.     CrossRef
  • Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) among Patients at a Movement Disorders Center
    Joy Antonelle de Marcaida, Jeffrey Lahrmann, Duarte Machado, Lawrence Bluth, Michelle Dagostine, Maria Moro-de Casillas, Elena Bortan, Sulada Kanchana, Mark Alberts
    Geriatrics.2020; 5(3): 54.     CrossRef
  • Update on Neurological Manifestations of SARS-CoV-2
    Hisham Valiuddin, Almir Kalajdzic, James Rosati, Kevin Boehm, Dominique Hill
    Western Journal of Emergency Medicine.2020;[Epub]     CrossRef
  • Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey
    Carla Piano, Francesco Bove, Tommaso Tufo, Isabella Imbimbo, Danilo Genovese, Alessandro Stefani, Massimo Marano, Antonella Peppe, Livia Brusa, Rocco Cerroni, Francesco Motolese, Enrico Di Stasio, Marianna Mazza, Antonio Daniele, Alessandro Olivi, Paolo C
    Frontiers in Neurology.2020;[Epub]     CrossRef
Update on Current Technologies for Deep Brain Stimulation in Parkinson’s Disease
Michelle Paff, Aaron Loh, Can Sarica, Andres M. Lozano, Alfonso Fasano
J Mov Disord. 2020;13(3):185-198.   Published online August 31, 2020
DOI: https://doi.org/10.14802/jmd.20052
  • 13,738 View
  • 597 Download
  • 34 Citations
AbstractAbstract PDF
Deep brain stimulation (DBS) is becoming increasingly central in the treatment of patients with Parkinson’s disease and other movement disorders. Recent developments in DBS lead and implantable pulse generator design provide increased flexibility for programming, potentially improving the therapeutic benefit of stimulation. Directional DBS leads may increase the therapeutic window of stimulation by providing a means of avoiding current spread to structures that might give rise to stimulation-related side effects. Similarly, control of current to individual contacts on a DBS lead allows for shaping of the electric field produced between multiple active contacts. The following review aims to describe the recent developments in DBS system technology and the features of each commercially available DBS system. The advantages of each system are reviewed, and general considerations for choosing the most appropriate system are discussed.

Citations

Citations to this article as recorded by  
  • Long-term motor outcomes of deep brain stimulation of the globus pallidus interna in Parkinson's disease patients: Five-year follow-up
    Yun Su Hwang, Sungyang Jo, Seung Hyun Lee, Nayoung Kim, Mi-Sun Kim, Sang Ryong Jeon, Sun Ju Chung
    Journal of the Neurological Sciences.2023; 444: 120484.     CrossRef
  • Brain stimulation treatments in epilepsy: Basic mechanisms and clinical advances
    Thomas J. Foutz, Michael Wong
    Biomedical Journal.2022; 45(1): 27.     CrossRef
  • Neurodegenerative disorders management: state-of-art and prospects of nano-biotechnology
    Raj Kumar, Keshaw Ram Aadil, Kunal Mondal, Yogendra Kumar Mishra, David Oupicky, Seeram Ramakrishna, Ajeet Kaushik
    Critical Reviews in Biotechnology.2022; 42(8): 1180.     CrossRef
  • Sleep and circadian rhythms in Parkinson’s disease and preclinical models
    Jeremy Hunt, Elizabeth J. Coulson, Rajendram Rajnarayanan, Henrik Oster, Aleksandar Videnovic, Oliver Rawashdeh
    Molecular Neurodegeneration.2022;[Epub]     CrossRef
  • Jose Delgado: A controversial trailblazer in neuromodulation
    Nicholas D. Lorusso, Uma R. Mohan, Joshua Jacobs
    Artificial Organs.2022; 46(4): 531.     CrossRef
  • Local and distant cortical responses to single pulse intracranial stimulation in the human brain are differentially modulated by specific stimulation parameters
    Angelique C. Paulk, Rina Zelmann, Britni Crocker, Alik S. Widge, Darin D. Dougherty, Emad N. Eskandar, Daniel S. Weisholtz, R. Mark Richardson, G. Rees Cosgrove, Ziv M. Williams, Sydney S. Cash
    Brain Stimulation.2022;[Epub]     CrossRef
  • Proceedings of the Ninth Annual Deep Brain Stimulation Think Tank: Advances in Cutting Edge Technologies, Artificial Intelligence, Neuromodulation, Neuroethics, Pain, Interventional Psychiatry, Epilepsy, and Traumatic Brain Injury
    Joshua K. Wong, Günther Deuschl, Robin Wolke, Hagai Bergman, Muthuraman Muthuraman, Sergiu Groppa, Sameer A. Sheth, Helen M. Bronte-Stewart, Kevin B. Wilkins, Matthew N. Petrucci, Emilia Lambert, Yasmine Kehnemouyi, Philip A. Starr, Simon Little, Juan Ans
    Frontiers in Human Neuroscience.2022;[Epub]     CrossRef
  • Past, Present, and Future of Deep Brain Stimulation: Hardware, Software, Imaging, Physiology and Novel Approaches
    Jessica Frey, Jackson Cagle, Kara A. Johnson, Joshua K. Wong, Justin D. Hilliard, Christopher R. Butson, Michael S. Okun, Coralie de Hemptinne
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Parkinson’s Disease Management via Wearable Sensors: A Systematic Review
    Huma Mughal, Abdul Rehman Javed, Muhammad Rizwan, Ahmad S. Almadhor, Natalia Kryvinska
    IEEE Access.2022; 10: 35219.     CrossRef
  • Conversion to Hybrid Deep Brain Stimulation System to Enable Multi‐Contact Fractionation Can be Therapeutic
    Disep I. Ojukwu, Allan R. Wang, Traci S. Hornbeck, Erika A. Lim, Jennifer Sharrard, Rohit Dhall, Vivek P. Buch, Casey H. Halpern
    Movement Disorders.2022; 37(6): 1321.     CrossRef
  • Developments in Deep Brain Stimulators for Successful Aging Towards Smart Devices—An Overview
    Angelito A. Silverio, Lean Angelo A. Silverio
    Frontiers in Aging.2022;[Epub]     CrossRef
  • Single-interface bioelectronic medicines—concept, clinical applications and preclinical data
    Cristian Sevcencu
    Journal of Neural Engineering.2022; 19(3): 031001.     CrossRef
  • Current Steering Using Multiple Independent Current Control Deep Brain Stimulation Technology Results in Distinct Neurophysiological Responses in Parkinson’s Disease Patients
    Jana Peeters, Alexandra Boogers, Tine Van Bogaert, Robin Gransier, Jan Wouters, Bart Nuttin, Myles Mc Laughlin
    Frontiers in Human Neuroscience.2022;[Epub]     CrossRef
  • Managing Intractable Symptoms of Parkinson's Disease: A Nonsurgical Approach Employing Infralow Frequency Neuromodulation
    Stella B. Legarda, P. Andreas Michas-Martin, Dana McDermott
    Frontiers in Human Neuroscience.2022;[Epub]     CrossRef
  • Directional Deep Brain Stimulation in the Treatment of Parkinson's Disease
    Akash Mishra, Ritesh A Ramdhani
    Neurology.2022; 18(1): 64.     CrossRef
  • Approach to the Treatment of Pediatric Dystonia
    Carolina Gorodetsky, Alfonso Fasano
    Dystonia.2022;[Epub]     CrossRef
  • CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics
    Tirthankar Sen, Rajkumar P. Thummer
    Neurotoxicity Research.2022; 40(5): 1597.     CrossRef
  • Encoding type, medication, and deep brain stimulation differentially affect memory-guided sequential reaching movements in Parkinson's disease
    Fabian J. David, Yessenia M. Rivera, Tara K. Entezar, Rishabh Arora, Quentin H. Drane, Miranda J. Munoz, Joshua M. Rosenow, Sepehr B. Sani, Gian D. Pal, Leonard Verhagen-Metman, Daniel M. Corcos
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Remote programming for subthalamic deep brain stimulation in Parkinson's disease
    Si Chen, Shu-jun Xu, Wei-guo Li, Teng Chen, Chao Li, Shuo Xu, Ning Yang, Yi-ming Liu
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Longevity of Deep Brain Stimulation Batteries; a Global Survey of Neurosurgeons and Neurologists
    Marwan Hariz, Gun‐Marie Hariz, Patric Blomstedt
    Movement Disorders.2021; 36(5): 1273.     CrossRef
  • Basic Tips: How Do I Start Programming Deep Brain Stimulation in Parkinson Disease Patients?
    Carolina Gorodetsky, Alfonso Fasano
    Movement Disorders Clinical Practice.2021; 8(4): 639.     CrossRef
  • Deep brain stimulation: Challenges at the tissue‐electrode interface and current solutions
    Emily Kolaya, Bonnie L. Firestein
    Biotechnology Progress.2021;[Epub]     CrossRef
  • An Update on Medical and Surgical Treatments of Parkinson’s Disease
    Dipali Nemade, Thyagarajan Subramanian, Vikram Shivkumar
    Aging and disease.2021; 12(4): 1021.     CrossRef
  • Experimental Characterization of Ferroelectric Capacitor Circuits for the Realization of Simply Designed Electroceuticals
    Yves Olsommer, Frank R. Ihmig
    Electronic Materials.2021; 2(3): 299.     CrossRef
  • Flexible vs. standard subthalamic stimulation in Parkinson disease: A double-blind proof-of-concept cross-over trial
    Derrick Soh, Ricardo Maciel, Musleh Algarni, Karlo Lizarraga, Aaron Loh, Jürgen Germann, Gavin Elias, Alexandre Boutet, Renato P. Munhoz, Suneil K. Kalia, Mojgan Hodaie, Andres M. Lozano, Alfonso Fasano
    Parkinsonism & Related Disorders.2021; 89: 93.     CrossRef
  • Telemedicine and Deep brain stimulation - Current practices and recommendations
    Vibhash D. Sharma, Delaram Safarpour, Shyamal H. Mehta, Nora Vanegas-Arroyave, Daniel Weiss, Jeffrey W. Cooney, Zoltan Mari, Alfonso Fasano
    Parkinsonism & Related Disorders.2021; 89: 199.     CrossRef
  • Subspace-based predictive control of Parkinson’s disease: A model-based study
    Mahboubeh Ahmadipour, Mojtaba Barkhordari-Yazdi, Saeid R. Seydnejad
    Neural Networks.2021; 142: 680.     CrossRef
  • Advances in Triboelectric Nanogenerators for Self‐Powered Regenerative Medicine
    Samira Parandeh, Niloofar Etemadi, Mahshid Kharaziha, Guorui Chen, Ardo Nashalian, Xiao Xiao, Jun Chen
    Advanced Functional Materials.2021; 31(47): 2105169.     CrossRef
  • Implantable Pulse Generators for Deep Brain Stimulation: Challenges, Complications, and Strategies for Practicality and Longevity
    Can Sarica, Christian Iorio-Morin, David H. Aguirre-Padilla, Ahmed Najjar, Michelle Paff, Anton Fomenko, Kazuaki Yamamoto, Ajmal Zemmar, Nir Lipsman, George M. Ibrahim, Clement Hamani, Mojgan Hodaie, Andres M. Lozano, Renato P. Munhoz, Alfonso Fasano, Sun
    Frontiers in Human Neuroscience.2021;[Epub]     CrossRef
  • Microstimulation Is a Promising Approach in Achieving Better Lead Placement in Subthalamic Nucleus Deep Brain Stimulation Surgery
    Lin Shi, Shiying Fan, Tianshuo Yuan, Huaying Fang, Jie Zheng, Zunyu Xiao, Yu Diao, Guanyu Zhu, Quan Zhang, Huanguang Liu, Hua Zhang, Fangang Meng, Jianguo Zhang, Anchao Yang
    Frontiers in Neurology.2021;[Epub]     CrossRef
  • Revisiting brain stimulation in Parkinson’s disease
    Carola A. Haas
    Science.2021; 374(6564): 153.     CrossRef
  • A New Implantable Closed-Loop Clinical Neural Interface: First Application in Parkinson’s Disease
    Mattia Arlotti, Matteo Colombo, Andrea Bonfanti, Tomasz Mandat, Michele Maria Lanotte, Elena Pirola, Linda Borellini, Paolo Rampini, Roberto Eleopra, Sara Rinaldo, Luigi Romito, Marcus L. F. Janssen, Alberto Priori, Sara Marceglia
    Frontiers in Neuroscience.2021;[Epub]     CrossRef
  • Update on Parkinson's Disease Therapy
    Rebecca M Gilbert
    Neurology.2021; 17(2): 92.     CrossRef
  • Deep Brain Stimulation for Parkinson's Disease: Currents Status and Emerging Concepts
    PareshK Doshi, Deepak Das
    Neurology India.2020; 68(8): 179.     CrossRef
Principles of Electrophysiological Assessments for Movement Disorders
Kai-Hsiang Stanley Chen, Robert Chen
J Mov Disord. 2020;13(1):27-38.   Published online January 31, 2020
DOI: https://doi.org/10.14802/jmd.19064
  • 10,395 View
  • 881 Download
  • 23 Citations
AbstractAbstract PDFSupplementary Material
Electrophysiological studies can provide objective and quantifiable assessments of movement disorders. They are useful in the diagnosis of hyperkinetic movement disorders, particularly tremors and myoclonus. The most commonly used measures are surface electromyography (sEMG), electroencephalography (EEG) and accelerometry. Frequency and coherence analyses of sEMG signals may reveal the nature of tremors and the source of the tremors. The effects of voluntary tapping, ballistic movements and weighting of the limbs can help to distinguish between organic and functional tremors. The presence of Bereitschafts-potentials and beta-band desynchronization recorded by EEG before movement onset provide strong evidence for functional movement disorders. EMG burst durations, distributions and muscle recruitment orders may identify and classify myoclonus to cortical, subcortical or spinal origins and help in the diagnosis of functional myoclonus. Organic and functional cervical dystonia can potentially be distinguished by EMG power spectral analysis. Several reflex circuits, such as the long latency reflex, blink reflex and startle reflex, can be elicited with different types of external stimuli and are useful in the assessment of myoclonus, excessive startle and stiff person syndrome. However, limitations of the tests should be recognized, and the results should be interpreted together with clinical observations.

Citations

Citations to this article as recorded by  
  • The clinical and electrophysiological investigation of tremor
    Günther Deuschl, Jos S. Becktepe, Michiel Dirkx, Dietrich Haubenberger, Anhar Hassan, Rick C. Helmich, Muthuraman Muthuraman, Pattamon Panyakaew, Petra Schwingenschuh, Kirsten E. Zeuner, Rodger J. Elble
    Clinical Neurophysiology.2022; 136: 93.     CrossRef
  • Remote measurement and home monitoring of tremor
    Zoltan Mari, Dietrich Haubenberger
    Journal of the Neurological Sciences.2022; 435: 120201.     CrossRef
  • Functional tremor
    Petra Schwingenschuh, Alberto J. Espay
    Journal of the Neurological Sciences.2022; 435: 120208.     CrossRef
  • Speech-induced action myoclonus
    Hugh D. Simpson, Joseph R. Duffy, Julie A.G. Stierwalt, J. Eric Ahlskog, Anhar Hassan
    Parkinsonism & Related Disorders.2022; 98: 41.     CrossRef
  • Simulation of the physical process of neural electromagnetic signal generation based on a simple but functional bionic Na+ channel
    Fan Wang, Jingjing Xu, Yanbin Ge, Shengyong Xu, Yanjun Fu, Caiyu Shi, Jianming Xue
    Chinese Physics B.2022; 31(6): 068701.     CrossRef
  • Functional Patients Referred for Deep Brain Stimulation: How Common Is it?
    Carolina Gorodetsky, Paula Azevedo, Alfonso Fasano
    Movement Disorders Clinical Practice.2022; 9(6): 841.     CrossRef
  • Myoclonus and other jerky movement disorders
    Sterre van der Veen, John N. Caviness, Yasmine E.M. Dreissen, Christos Ganos, Abubaker Ibrahim, Johannes H.T.M. Koelman, Ambra Stefani, Marina A.J. Tijssen
    Clinical Neurophysiology Practice.2022; 7: 285.     CrossRef
  • Posthypoxic Segmental Spinal “Flutter”-Like Myoclonus
    BobyV Maramattom
    Neurology India.2022; 70(5): 2202.     CrossRef
  • Contemporary clinical neurophysiology applications in dystonia
    Petr Kaňovský, Raymond Rosales, Pavel Otruba, Martin Nevrlý, Lenka Hvizdošová, Robert Opavský, Michaela Kaiserová, Pavel Hok, Kateřina Menšíková, Petr Hluštík, Martin Bareš
    Journal of Neural Transmission.2021; 128(4): 509.     CrossRef
  • Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders
    Gerard Saranza, Daniel Vargas-Mendez, Anthony E. Lang, Robert Chen
    Clinical Neurophysiology Practice.2021; 6: 103.     CrossRef
  • Peribuccal and pharyngeal myorhythmia as a presenting symptom of hypertrophic olivary degeneration: Expert commentary
    Robert Chen
    Parkinsonism & Related Disorders.2021; 85: 144.     CrossRef
  • Nano‐dielectrics in biosystems
    Jingjing Xu, Fan Wang, Yihan Song, Song Ge, Shengyong Xu
    IET Nanodielectrics.2021; 4(4): 179.     CrossRef
  • Asterixis of peripheral origin: isolated lower limb asterixis in Guillain–Barre syndrome
    Boby Varkey Maramattom
    Acta Neurologica Belgica.2021;[Epub]     CrossRef
  • Jaw Pain and Oromandibular Dysfunction After a Complex Hospital Course
    Sarah Smith, Ny-Ying Lam
    American Journal of Physical Medicine & Rehabilitation.2021; 100(5): e62.     CrossRef
  • Factors Influencing the Surgical Decision in Dystonia Patients Referred for Deep Brain Stimulation
    Carolina Gorodetsky, Paula Azevedo, Carolina Candeias da Silva, Alfonso Fasano
    Toxins.2021; 13(8): 511.     CrossRef
  • Tremor Syndromes: An Updated Review
    Abhishek Lenka, Joseph Jankovic
    Frontiers in Neurology.2021;[Epub]     CrossRef
  • The diagnostic value of clinical neurophysiology in hyperkinetic movement disorders: A systematic review
    S. van der Veen, M.R. Klamer, J.W.J. Elting, J.H.T.M. Koelman, A.M.M. van der Stouwe, M.A.J. Tijssen
    Parkinsonism & Related Disorders.2021; 89: 176.     CrossRef
  • Wearable monitoring of positive and negative myoclonus in progressive myoclonic epilepsy type 1
    Saara M. Rissanen, Jelena Hyppönen, Katri Silvennoinen, Laura Säisänen, Pasi A. Karjalainen, Esa Mervaala, Reetta Kälviäinen
    Clinical Neurophysiology.2021; 132(10): 2464.     CrossRef
  • Surface electromyography for evaluating patients with oromandibular dystonia
    Jae-Hyung Kim, Byung-Gook Kim, Yeong-Gwan Im
    CRANIO®.2021; : 1.     CrossRef
  • Evaluation of movement and brain activity
    Mark Hallett, Lourdes M. DelRosso, Rodger Elble, Raffaele Ferri, Fay B. Horak, Stephan Lehericy, Martina Mancini, Masao Matsuhashi, Riki Matsumoto, Muthuraman Muthuraman, Jan Raethjen, Hiroshi Shibasaki
    Clinical Neurophysiology.2021; 132(10): 2608.     CrossRef
  • Clinical and Psychological Aspects of Myoclonus in Different age Periods
    Т.А. Литовченко, О.Ю. Сухоносова
    Психиатрия, психотерапия и клиническая психология.2021; (2): 303.     CrossRef
  • Minimum Electromyographic Burst Duration in Healthy Controls: Implications for Electrodiagnosis in Movement Disorders
    Alexis F. Collins, Steven T.R. Brown, Mark R. Baker
    Movement Disorders Clinical Practice.2020; 7(7): 827.     CrossRef
  • Physiology-Based Treatment of Myoclonus
    Ashley B. Pena, John N. Caviness
    Neurotherapeutics.2020; 17(4): 1665.     CrossRef
Immune-Mediated Cerebellar Ataxias: Clinical Diagnosis and Treatment Based on Immunological and Physiological Mechanisms
Hiroshi Mitoma, Mario Manto, Marios Hadjivassiliou
J Mov Disord. 2021;14(1):10-28.   Published online January 12, 2021
DOI: https://doi.org/10.14802/jmd.20040
  • 7,246 View
  • 537 Download
  • 18 Citations
AbstractAbstract PDF
Since the first description of immune-mediated cerebellar ataxias (IMCAs) by Charcot in 1868, several milestones have been reached in our understanding of this group of neurological disorders. IMCAs have diverse etiologies, such as gluten ataxia, postinfectious cerebellitis, paraneoplastic cerebellar degeneration, opsoclonus myoclonus syndrome, anti-GAD ataxia, and primary autoimmune cerebellar ataxia. The cerebellum, a vulnerable autoimmune target of the nervous system, has remarkable capacities (collectively known as the cerebellar reserve, closely linked to plasticity) to compensate and restore function following various pathological insults. Therefore, good prognosis is expected when immune-mediated therapeutic interventions are delivered during early stages when the cerebellar reserve can be preserved. However, some types of IMCAs show poor responses to immunotherapies, even if such therapies are introduced at an early stage. Thus, further research is needed to enhance our understanding of the autoimmune mechanisms underlying IMCAs, as such research could potentially lead to the development of more effective immunotherapies. We underscore the need to pursue the identification of robust biomarkers.

Citations

Citations to this article as recorded by  
  • Gluten Ataxia: an Underdiagnosed Condition
    Marios Hadjivassiliou, R. A. Grϋnewald
    The Cerebellum.2022; 21(4): 620.     CrossRef
  • Clinical Problem Solving: Decreased Level of Consciousness and Unexplained Hydrocephalus
    Naomi Niznick, Ronda Lun, Daniel A. Lelli, Tadeu A. Fantaneanu
    The Neurohospitalist.2022; 12(2): 312.     CrossRef
  • Pharmacotherapy of cerebellar and vestibular disorders
    João Lemos, Mario Manto
    Current Opinion in Neurology.2022; 35(1): 118.     CrossRef
  • Advances in the Pathogenesis of Auto-antibody-Induced Cerebellar Synaptopathies
    Hiroshi Mitoma, Mario Manto
    The Cerebellum.2022;[Epub]     CrossRef
  • A Breakdown of Immune Tolerance in the Cerebellum
    Christiane S. Hampe, Hiroshi Mitoma
    Brain Sciences.2022; 12(3): 328.     CrossRef
  • Acute Cerebellar Inflammation and Related Ataxia: Mechanisms and Pathophysiology
    Md. Sorwer Alam Parvez, Gen Ohtsuki
    Brain Sciences.2022; 12(3): 367.     CrossRef
  • A Case Report of Anti-PCA-2-Positive Autoimmune Cerebellitis
    霞 董
    Advances in Clinical Medicine.2022; 12(04): 3272.     CrossRef
  • Cell-Autonomous Processes That Impair Xenograft Survival into the Cerebellum
    Lorenzo Magrassi, Giulia Nato, Domenico Delia, Annalisa Buffo
    The Cerebellum.2022; 21(5): 821.     CrossRef
  • Diagnosis and Clinical Features in Autoimmune-Mediated Movement Disorders
    Pei-Chen Hsieh, Yih-Ru Wu
    Journal of Movement Disorders.2022; 15(2): 95.     CrossRef
  • Autoimmune cerebellar ataxia associated with anti-leucine-rich glioma-inactivated protein 1 antibodies: Two pediatric cases
    Zhang Weihua, Ren Haitao, Deng Jie, Ren Changhong, Zhou Ji, Zhou Anna, Guan Hongzhi, Ren Xiaotun
    Journal of Neuroimmunology.2022; 370: 577918.     CrossRef
  • Anti-dipeptidyl-peptidase-like protein 6 encephalitis with pure cerebellar ataxia: a case report
    Jing Lin, Min Zhu, Xiaocheng Mao, Zeqing Jin, Meihong Zhou, Daojun Hong
    BMC Neurology.2022;[Epub]     CrossRef
  • Central Positional Nystagmus
    Ana Inês Martins, André Jorge, João Lemos
    Current Treatment Options in Neurology.2022; 24(10): 453.     CrossRef
  • Paraneoplastic Ataxia: Antibodies at the Forefront Have Become Routine Biomarkers
    Lazaros C. Triarhou, Mario Manto
    The Cerebellum.2022;[Epub]     CrossRef
  • Rare Etiologies in Immune-Mediated Cerebellar Ataxias: Diagnostic Challenges
    Marios Hadjivassiliou, Mario Manto, Hiroshi Mitoma
    Brain Sciences.2022; 12(9): 1165.     CrossRef
  • Paraneoplastic syndromes in neuro-ophthalmology
    SimonJ Hickman
    Annals of Indian Academy of Neurology.2022; 25(8): 101.     CrossRef
  • Immunotherapies for the Effective Treatment of Primary Autoimmune Cerebellar Ataxia: a Case Series
    Jiao Li, Bo Deng, Wenli Song, Keru Li, Jingwen Ai, Xiaoni Liu, Haocheng Zhang, Yi Zhang, Ke Lin, Guofu Shao, Chunfeng Liu, Wenhong Zhang, Xiangjun Chen, Yanlin Zhang
    The Cerebellum.2022;[Epub]     CrossRef
  • Stiff-Eye Syndrome—Anti-GAD Ataxia Presenting with Isolated Ophthalmoplegia: A Case Report
    Abel Dantas Belém, Thaís de Maria Frota Vasconcelos, Rafael César dos Anjos de Paula, Francisco Bruno Santana da Costa, Pedro Gustavo Barros Rodrigues, Isabelle de Sousa Pereira, Paulo Roberto de Arruda Tavares, Gabriela Studart Galdino, Daniel Aguiar Dia
    Brain Sciences.2021; 11(7): 932.     CrossRef
  • Update on Paraneoplastic Cerebellar Degeneration
    Philipp Alexander Loehrer, Lara Zieger, Ole J. Simon
    Brain Sciences.2021; 11(11): 1414.     CrossRef
Emerging Concepts of Motor Reserve in Parkinson’s Disease
Seok Jong Chung, Jae Jung Lee, Phil Hyu Lee, Young H. Sohn
J Mov Disord. 2020;13(3):171-184.   Published online August 31, 2020
DOI: https://doi.org/10.14802/jmd.20029
  • 7,243 View
  • 270 Download
  • 16 Citations
AbstractAbstract PDF
The concept of cognitive reserve (CR) in Alzheimer’s disease (AD) explains the differences between individuals in their susceptibility to AD-related pathologies. An enhanced CR may lead to less cognitive deficits despite severe pathological lesions. Parkinson’s disease (PD) is also a common neurodegenerative disease and is mainly characterized by motor dysfunction related to striatal dopaminergic depletion. The degree of motor deficits in PD is closely correlated to the degree of dopamine depletion; however, significant individual variations still exist. Therefore, we hypothesized that the presence of motor reserve (MR) in PD explains the individual differences in motor deficits despite similar levels of striatal dopamine depletion. Since 2015, we have performed a series of studies investigating MR in de novo patients with PD using the data of initial clinical presentation and dopamine transporter PET scan. In this review, we summarized the results of these published studies. In particular, some premorbid experiences (i.e., physical activity and education) and modifiable factors (i.e., body mass index and white matter hyperintensity on brain image studies) could modulate an individual’s capacity to tolerate PD pathology, which can be maintained throughout disease progression.

Citations

Citations to this article as recorded by  
  • Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinson’s Disease
    Seong Ho Jeong, Seok Jong Chung, Han Soo Yoo, Jin Ho Jung, Kyoungwon Baik, Yang Hyun Lee, Phil Hyu Lee, Young H. Sohn
    Journal of Parkinson's Disease.2022; 12(1): 129.     CrossRef
  • Parkinsonism and cerebrovascular disease
    Manisha Narasimhan, Raymond Schwartz, Glenda Halliday
    Journal of the Neurological Sciences.2022; 433: 120011.     CrossRef
  • Impact of α‐synuclein spreading on the nigrostriatal dopaminergic pathway depends on the onset of the pathology
    Fanfan Sun, Armando G. Salinas, Severin Filser, Sonja Blumenstock, Jose Medina‐Luque, Jochen Herms, Carmelo Sgobio
    Brain Pathology.2022;[Epub]     CrossRef
  • Premorbid cancer and motor reserve in patients with Parkinson’s disease
    Yoon-Sang Oh, Sang-Won Yoo, Chul Hyoung Lyoo, Kwang-Soo Lee, Joong-Seok Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • Behavioral Reserve in Behavioral Variant Frontotemporal Dementia
    Su Hong Kim, Yae Ji Kim, Byung Hwa Lee, Peter Lee, Ji Hyung Park, Sang Won Seo, Yong Jeong
    Frontiers in Aging Neuroscience.2022;[Epub]     CrossRef
  • Identifying the white matter structural network of motor reserve in early Parkinson's disease
    Yae Ji Kim, Chan Wook Park, Hye Won Shin, Hye Sun Lee, Yun Joong Kim, Mijin Yun, Phil Hyu Lee, Young H. Sohn, Yong Jeong, Seok Jong Chung
    Parkinsonism & Related Disorders.2022; 102: 108.     CrossRef
  • Motor progression marker for newly diagnosed drug‐naïve patients with Parkinson's disease: A resting‐state functional MRI study
    Yanbing Hou, Lingyu Zhang, Ruwei Ou, Qianqian Wei, Xiaojing Gu, Kuncheng Liu, Junyu Lin, Tianmi Yang, Yi Xiao, Qiyong Gong, Huifang Shang
    Human Brain Mapping.2022;[Epub]     CrossRef
  • Comparison of disease progression between brain-predominant Parkinson's disease versus Parkinson's disease with body-involvement phenotypes
    Dong-Woo Ryu, Sang-Won Yoo, Yoon-Sang Oh, Kwang-Soo Lee, Seunggyun Ha, Joong-Seok Kim
    Neurobiology of Disease.2022; 174: 105883.     CrossRef
  • Genetically-informed prediction of short-term Parkinson’s disease progression
    Hossein J. Sadaei, Aldo Cordova-Palomera, Jonghun Lee, Jaya Padmanabhan, Shang-Fu Chen, Nathan E. Wineinger, Raquel Dias, Daria Prilutsky, Sandor Szalma, Ali Torkamani
    npj Parkinson's Disease.2022;[Epub]     CrossRef
  • Potential Link Between Cognition and Motor Reserve in Patients With Parkinson’s Disease
    Seok Jong Chung, Yae Ji Kim, Yun Joong Kim, Hye Sun Lee, Mijin Yun, Phil Hyu Lee, Yong Jeong, Young H. Sohn
    Journal of Movement Disorders.2022; 15(3): 249.     CrossRef
  • The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?
    Merle C. Hoenig, Verena Dzialas, Alexander Drzezga, Thilo van Eimeren
    Movement Disorders.2022;[Epub]     CrossRef
  • Effectiveness and safety of electroacupuncture in treating Parkinson disease
    Wei Xu, Sha OuYang, Zhenhai Chi, ZhiQin Wang, DaoCheng Zhu, RiXin Chen, GenPing Zhong, FengTing Zhang, GuiQin Zhou, SiWei Duan, Lin Jiao
    Medicine.2021; 100(10): e25095.     CrossRef
  • Differences in cause and 12-month follow-up outcome of parkinsonian symptoms in depressed older adults treated with antipsychotics: a case series
    Anastasios Politis, Nikolaos Kokras, Michael Souvatzoglou, Kostas Siarkos, Panagiotis Toulas, Constantin Potagas, Theodoros Hatzipanagiotou, Georgios Limouris, Panagiotis Alexopoulos
    BMC Psychiatry.2021;[Epub]     CrossRef
  • Effectiveness and safety of moxibustion for Parkinson disease
    Yonghui Hou, Baile Ning, Yamin Liu, Ying Liu, Wenbin Fu, Zehuai Wen
    Medicine.2021; 100(23): e26256.     CrossRef
  • Glucocerebrosidase Mutations and Motor Reserve in Parkinson’s Disease
    Seok Jong Chung, Phil Hyu Lee, Young H. Sohn, Yun Joong Kim
    Journal of Parkinson's Disease.2021; 11(4): 1715.     CrossRef
  • Analysis of pupillometer results according to disease stage in patients with Parkinson’s disease
    Sooyeoun You, Jeong-Ho Hong, Joonsang Yoo
    Scientific Reports.2021;[Epub]     CrossRef
Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
Junghwan Shin, Han-Joon Kim, Beomseok Jeon
J Mov Disord. 2020;13(1):11-19.   Published online December 19, 2019
DOI: https://doi.org/10.14802/jmd.19057
  • 6,702 View
  • 395 Download
  • 15 Citations
AbstractAbstract PDF
α-Synuclein and tau deposition in the central nervous system is responsible for various parkinsonian syndromes, including Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. Emerging evidence has suggested that pathologic α-synuclein and tau are transmitted from cell to cell and further accelerate the aggregation of pathologic proteins in neighboring cells. Furthermore, extracellular pathologic proteins have also been reported to provoke inflammatory responses that lead to neurodegeneration. Therefore, immunotherapies targeting extracellular α-synuclein and tau have been proposed as potential disease-modifying strategies. In this review, we summarize completed phase I trials and ongoing phase II trials of immunotherapies against α-synuclein and tau and further discuss concerns and hurdles to overcome in the future.

Citations

Citations to this article as recorded by  
  • Modeling the dynamics of innate and adaptive immune response to Parkinson's disease with immunotherapy
    Salma M. Al-Tuwairqi, Asma A. Badrah
    AIMS Mathematics.2023; 8(1): 1800.     CrossRef
  • Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
    Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare
    Acta Neuropathologica.2022; 143(1): 55.     CrossRef
  • Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies
    Changyoun Kim, Armine Hovakimyan, Karen Zagorski, Tatevik Antonyan, Irina Petrushina, Hayk Davtyan, Gor Chailyan, Jonathan Hasselmann, Michiyo Iba, Anthony Adame, Edward Rockenstein, Marcell Szabo, Mathew Blurton-Jones, David H. Cribbs, Anahit Ghochikyan,
    npj Vaccines.2022;[Epub]     CrossRef
  • Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy
    Thuy Thi Lai, Yun Joong Kim, Hyeo-il Ma, Young Eun Kim
    Journal of Movement Disorders.2022; 15(1): 1.     CrossRef
  • Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies
    Dhanya Vijayakumar, Joseph Jankovic
    CNS Drugs.2022; 36(4): 327.     CrossRef
  • Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases
    Urmi Sengupta, Rakez Kayed
    Progress in Neurobiology.2022; 214: 102270.     CrossRef
  • Modeling the dynamics of innate immune response to Parkinson disease with therapeutic approach
    Asma Badrah, Salma Al-Tuwairqi
    Physical Biology.2022; 19(5): 056004.     CrossRef
  • Potential of food-derived bioactive peptides in alleviation and prevention of Alzheimer's disease
    Le Zhao, Dan Li, Xiaofen Qi, Kaifang Guan, Haoran Chen, Rongchun Wang, Ying Ma
    Food & Function.2022; 13(21): 10851.     CrossRef
  • Harnessing the immune system for the treatment of Parkinson’s disease
    Vinata Vedam-Mai
    Brain Research.2021; 1758: 147308.     CrossRef
  • The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease
    Katja Badanjak, Sonja Fixemer, Semra Smajić, Alexander Skupin, Anne Grünewald
    International Journal of Molecular Sciences.2021; 22(9): 4676.     CrossRef
  • Viral alpha-synuclein knockdown prevents spreading synucleinopathy
    Sindhu Menon, Rikke H Kofoed, Fadl Nabbouh, Kristiana Xhima, Yasmeen Al-Fahoum, Tammy Langman, Howard T J Mount, Lamya S Shihabuddin, S Pablo Sardi, Paul E Fraser, Joel C Watts, Isabelle Aubert, Anurag Tandon
    Brain Communications.2021;[Epub]     CrossRef
  • Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
    Somin Kwon, Michiyo Iba, Changyoun Kim, Eliezer Masliah
    Neurotherapeutics.2020; 17(3): 935.     CrossRef
  • The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease
    Kyu-Young Sim, Kyeong Chan Im, Sung-Gyoo Park
    International Journal of Molecular Sciences.2020; 21(15): 5295.     CrossRef
  • Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
    Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll
    Alzheimer's Research & Therapy.2020;[Epub]     CrossRef
  • New Insights Into Drug Discovery Targeting Tau Protein
    Yoshiyuki Soeda, Akihiko Takashima
    Frontiers in Molecular Neuroscience.2020;[Epub]     CrossRef
Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions
Masahito Yamada, Junji Komatsu, Keiko Nakamura, Kenji Sakai, Miharu Samuraki-Yokohama, Kenichi Nakajima, Mitsuhiro Yoshita
J Mov Disord. 2020;13(1):1-10.   Published online November 8, 2019
DOI: https://doi.org/10.14802/jmd.19052
  • 21,044 View
  • 1,498 Download
  • 15 Citations
AbstractAbstract PDF
The aim of this article is to describe the 2017 revised consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) with future directions for the diagnostic criteria. The criteria for the clinical diagnosis of probable and possible DLB were first published as the first consensus report in 1996 and were revised in the third consensus report in 2005. After discussion at the International DLB Conference in Fort Lauderdale, Florida, USA, in 2015, the International DLB Consortium published the fourth consensus report including the revised consensus criteria in 2017. The 2017 revised criteria clearly distinguish between clinical features and diagnostic biomarkers. Significant new information about previously reported aspects of DLB has been incorporated, with increased diagnostic weighting given to rapid eye movement (REM) sleep behavior disorder (RBD) and iodine-123-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. Future directions include the development of the criteria for early diagnosis (prodromal DLB) and the establishment of new biomarkers that directly indicate Lewy-related pathology, including α-synuclein imaging, biopsies of peripheral tissues (skin, etc.) for the demonstration of α-synuclein deposition, and biochemical markers (cerebrospinal fluid/blood), as well as the pathological evaluation of the sensitivity and specificity of the 2017 revised diagnostic criteria. In conclusion, the revised consensus criteria for the clinical diagnosis of DLB were reported with the incorporation of new information about DLB in 2017. Future directions include the development of the criteria for early diagnosis and the establishment of biomarkers directly indicative of Lewy-related pathology.

Citations

Citations to this article as recorded by  
  • Autonomic symptoms are predictive of dementia with Lewy bodies
    Wenzheng Hu, Shuai Liu, Fei Wang, Han Zhu, Xiaoshan Du, Lingyun Ma, Jinghuan Gan, Hao Wu, Xiaodan Wang, Yong Ji
    Parkinsonism & Related Disorders.2022; 95: 1.     CrossRef
  • Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?
    Daniele Urso, Valentina Gnoni, Marco Filardi, Giancarlo Logroscino
    Frontiers in Psychiatry.2022;[Epub]     CrossRef
  • Clinical Trajectories at the End of Life in Autopsy-Confirmed Dementia Patients With Alzheimer Disease and Lewy Bodies Pathologies
    Yian Gu, Anton Kociolek, Kayri K. Fernandez, Stephanie A. Cosentino, Carolyn Wei Zhu, Zhezhen Jin, James B. Leverenz, Yaakov B. Stern
    Neurology.2022; 98(21): e2140.     CrossRef
  • Diagnostic Performance for Differential Diagnosis of Atypical Parkinsonian Syndromes from Parkinson’s Disease Using Quantitative Indices of 18F-FP-CIT PET/CT
    Miju Cheon, Seung Min Kim, Sang-Won Ha, Min Ju Kang, Hea-Eun Yang, Jang Yoo
    Diagnostics.2022; 12(6): 1402.     CrossRef
  • The promise of amplification assays for accurate early detection of α-synucleinopathies: A review
    Regina Kurapova, Leonidas Chouliaras, John T. O'Brien
    Experimental Gerontology.2022; 165: 111842.     CrossRef
  • Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
    Annette Janzen, David Vadasz, Jan Booij, Markus Luster, Damiano Librizzi, Martin T. Henrich, Lars Timmermann, Mahboubeh Habibi, Elisabeth Sittig, Geert Mayer, Fanni Geibl, Wolfgang Oertel
    Journal of Parkinson's Disease.2022; 12(6): 1921.     CrossRef
  • A Systematic Review and Comparison of Neurocognitive Features of Late-Life Attention-Deficit/Hyperactivity Disorder and Dementia With Lewy Bodies
    Jennifer L. Prentice, Morgan J. Schaeffer, Alexandra K. Wall, Brandy L. Callahan
    Journal of Geriatric Psychiatry and Neurology.2021; 34(5): 466.     CrossRef
  • Dementia with Lewy bodies in first-generation immigrants in a European memory clinic
    Kurt Segers, Florence Benoit, Jean-Marie Meyts, Gérald Glibert, Sophie Levy, Murielle Surquin
    Acta Neurologica Belgica.2021; 121(1): 219.     CrossRef
  • The development of new method to differentiate between Dementia with Lewy bodies and Alzheimer’s disease by cerebral perfusion SPECT-comparison to CIScore
    Gaku Honda, Shigeki Nagamachi, Masanari Nonokuma, Koichi Takano, Yasuo Kuwabara, Kengo Yoshimitsu, Hitoshi Iida, Koji Ogomori, Hiroaki Kawasaki, Yoshio Tsuboi
    Japanese Journal of Radiology.2021; 39(2): 198.     CrossRef
  • Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease
    Xue-Bing Ding, Xin-Xin Wang, Dan-Hao Xia, Han Liu, Hai-Yan Tian, Yu Fu, Yong-Kang Chen, Chi Qin, Jiu-Qi Wang, Zhi Xiang, Zhong-Xian Zhang, Qin-Chen Cao, Wei Wang, Jia-Yi Li, Erxi Wu, Bei-Sha Tang, Ming-Ming Ma, Jun-Fang Teng, Xue-Jing Wang
    Nature Medicine.2021; 27(3): 411.     CrossRef
  • Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences
    Dariusz Koziorowski, Monika Figura, Łukasz M. Milanowski, Stanisław Szlufik, Piotr Alster, Natalia Madetko, Andrzej Friedman
    Cells.2021; 10(3): 656.     CrossRef
  • Advances in computerized MRI‐based biomarkers in Alzheimer’s disease
    Raymond Wong, Yishan Luo, Vincent Chung-tong Mok, Lin Shi
    Brain Science Advances.2021; 7(1): 26.     CrossRef
  • Convolutional neural network-based automatic heart segmentation and quantitation in 123I-metaiodobenzylguanidine SPECT imaging
    Shintaro Saito, Kenichi Nakajima, Lars Edenbrandt, Olof Enqvist, Johannes Ulén, Seigo Kinuya
    EJNMMI Research.2021;[Epub]     CrossRef
  • A direct comparison of the 2005 and 2017 criteria for dementia with Lewy bodies
    Kurt Segers, Florence Benoit, Jean‐Marie Meyts, Gerald Glibert, Murielle Surquin
    Psychogeriatrics.2020; 20(5): 785.     CrossRef
  • Calibrated scintigraphic imaging procedures improve quantitative assessment of the cardiac sympathetic nerve activity
    Koichi Okuda, Kenichi Nakajima, Chiemi Kitamura, Yumiko Kirihara, Mitsumasa Hashimoto, Seigo Kinuya
    Scientific Reports.2020;[Epub]     CrossRef
Original Articles
Health-Related Quality of Life for Parkinson’s Disease Patients and Their Caregivers
Michal Lubomski, Ryan L. Davis, Carolyn M. Sue
J Mov Disord. 2021;14(1):42-52.   Published online January 12, 2021
DOI: https://doi.org/10.14802/jmd.20079
  • 5,966 View
  • 203 Download
  • 13 Citations
AbstractAbstract PDF
Objective
Motor and non-motor symptoms (NMS) negatively impact the health-related quality of life (HRQoL) for individuals with Parkinson’s disease (PD), as well as their caregivers. NMS can emerge decades prior to the manifestation of motor symptoms but often go unrecognized and therefore untreated. To guide clinical management, we surveyed differences and identified factors that influence HRQoL in a cohort of PD patients and family caregivers.
Methods
A total of 103 PD patients were compared with 81 caregivers. Outcome measures collected from validated questionnaires included generic and disease-specific HRQoL assessments, depression frequency and severity, constipation severity, upper and lower gastrointestinal symptoms, physical activity and motor symptom severity.
Results
PD patients reported significantly decreased physical and mental HRQoL compared to their caregivers (both p < 0.001). Unemployment, the need for social support services, rehabilitation use, REM sleep behavior disorder, impulse control disorders and features suggestive of increasing disease severity hallmarked by increasing PD duration, higher MDS UPDRS-III (Movement Disorder Society–Unified Parkinson’s Disease Rating Scale–Part III) scores, higher daily levodopa equivalence dose and motor fluctuations were consistent with a lower HRQoL in our PD cohort. Furthermore, decreased physical activity, chronic pain, depression, constipation and upper gastrointestinal dysfunction (particularly indigestion, excess fullness and bloating) suggested vulnerability to reduced HRQoL. Overall, PD patients perceived their health to decline by 12% more than their caregivers did over a 1-year period.
Conclusion
PD patients reported decreased HRQoL, with both motor symptoms and NMS negatively impacting HRQoL. Our findings support the routine clinical screening of HRQoL in PD patients to identify and address modifiable factors.

Citations

Citations to this article as recorded by  
  • The impact of device-assisted therapies on the gut microbiome in Parkinson’s disease
    Michal Lubomski, Xiangnan Xu, Andrew J. Holmes, Jean Y. H. Yang, Carolyn M. Sue, Ryan L. Davis
    Journal of Neurology.2022; 269(2): 780.     CrossRef
  • Predictive Model of Quality of Life in Patients with Parkinson’s Disease
    Eduardo Candel-Parra, María Pilar Córcoles-Jiménez, Victoria Delicado-Useros, Marta Carolina Ruiz-Grao, Antonio Hernández-Martínez, Milagros Molina-Alarcón
    International Journal of Environmental Research and Public Health.2022; 19(2): 672.     CrossRef
  • Die neue Parkinson-Schmerzklassifikation (PSK)
    V. Mylius, S. Perez Lloret, C. S. Brook, M. T. Krüger, S. Hägele-Link, R. Gonzenbach, J. Kassubek, S. Bohlhalter, J. P. Lefaucheur, L. Timmermann, G. Kägi, F. Brugger, D. Ciampi de Andrade, J. C. Möller
    Der Nervenarzt.2022; 93(10): 1019.     CrossRef
  • Quantification Analysis of Sleep Based on Smartwatch Sensors for Parkinson’s Disease
    Yi-Feng Ko, Pei-Hsin Kuo, Ching-Fu Wang, Yu-Jen Chen, Pei-Chi Chuang, Shih-Zhang Li, Bo-Wei Chen, Fu-Chi Yang, Yu-Chun Lo, Yi Yang, Shuan-Chu Vina Ro, Fu-Shan Jaw, Sheng-Huang Lin, You-Yin Chen
    Biosensors.2022; 12(2): 74.     CrossRef
  • Gastrointestinal Dysfunction Impact on Life Quality in a Cohort of Russian Patients with Parkinson’s Disease I-III H&Y Stage
    A. A. Pilipovich, O. V. Vorob’eva, S. A. Makarov, N. N. Shindryaeva, Yu D. Vorob’eva, Seyed-Mohammad Fereshtehnejad
    Parkinson's Disease.2022; 2022: 1.     CrossRef
  • Nutritional Intake and Gut Microbiome Composition Predict Parkinson’s Disease
    Michal Lubomski, Xiangnan Xu, Andrew J. Holmes, Samuel Muller, Jean Y. H. Yang, Ryan L. Davis, Carolyn M. Sue
    Frontiers in Aging Neuroscience.2022;[Epub]     CrossRef
  • The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies
    Michal Lubomski, Xiangnan Xu, Andrew J. Holmes, Samuel Muller, Jean Y. H. Yang, Ryan L. Davis, Carolyn M. Sue
    Frontiers in Aging Neuroscience.2022;[Epub]     CrossRef
  • Characteristics and quality of life of substance users and their caregivers
    Jadranka M. Maksimovic, Olivera B. Sbutega, Aleksandar D. Pavlovic, Hristina D. Vlajinac, Ivana I. Kavecan, Isidora S. Vujcic, Sandra B. Grujicic Sipetic
    Medicine.2022; 101(31): e29699.     CrossRef
  • Defining the unknowns for cell therapies in Parkinson's disease
    Emma L. Lane, Mariah J. Lelos
    Disease Models & Mechanisms.2022;[Epub]     CrossRef
  • Increased Added Sugar Consumption Is Common in Parkinson's Disease
    Natalie C. Palavra, Michal Lubomski, Victoria M. Flood, Ryan L. Davis, Carolyn M. Sue
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Relationship Satisfaction in People with Parkinson’s Disease and Their Caregivers: A Cross-Sectional Observational Study
    Johanne Heine, Hannah von Eichel, Selma Staege, Günter U. Höglinger, Florian Wegner, Martin Klietz
    Brain Sciences.2021; 11(6): 822.     CrossRef
  • Diagnosis and Management of Pain in Parkinson's Disease: A New Approach
    Veit Mylius, Jens Carsten Möller, Stephan Bohlhalter, Daniel Ciampi de Andrade, Santiago Perez Lloret
    Drugs & Aging.2021; 38(7): 559.     CrossRef
  • Cognitive Influences in Parkinson's Disease Patients and Their Caregivers: Perspectives From an Australian Cohort
    Michal Lubomski, Ryan L. Davis, Carolyn M. Sue
    Frontiers in Neurology.2021;[Epub]     CrossRef
Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson’s Disease
Han Soo Yoo, Seok Jong Chung, Yang Hyun Lee, Byoung Seok Ye, Young H. Sohn, Phil Hyu Lee
J Mov Disord. 2020;13(2):133-141.   Published online April 6, 2020
DOI: https://doi.org/10.14802/jmd.19082
  • 6,638 View
  • 247 Download
  • 13 Citations
AbstractAbstract PDFSupplementary Material
Objective
To investigate whether baseline olfactory dysfunction in Parkinson’s disease (PD) patients is associated with baseline and longitudinal motor and cognitive function.
Methods
We recruited 228 drug-naïve PD patients who were followed for a mean of 6 years. Patients underwent the Cross-Cultural Smell Identification Test (CCSIT), a neuropsychological test, and N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane positron emission tomography within 6 months of the baseline evaluation. Olfactory dysfunction was categorized as normosmia (CCSIT score ≥ 9), hyposmia (CCSIT score 5–8), and anosmia (CCSIT score ≤ 4). During the follow-up period, we investigated changes in the levodopa-equivalent dose (LED) and the occurrence of wearing-off, levodopa-induced dyskinesia, and dementia.
Results
Among the PD patients, 80.7% were hyposmic at the time of diagnosis, and 26.1% were anosmic. Baseline olfactory dysfunction was not associated with either initial parkinsonian motor symptoms or with the longitudinal LED increment and motor complications. Meanwhile, the anosmic group had lower baseline scores on the Korea version of the Boston Naming Test and Stroop color reading test than the normosmic and hyposmic groups. The anosmic group exhibited a higher rate of conversion to dementia than the normosmic [adjusted hazard ratio (HR) 3.99, 95% confidence interval (CI) 1.08–14.72] and hyposmic (adjusted HR 2.48, 95% CI 1.15–5.32) PD groups, regardless of baseline motor deficits and cognitive status.
Conclusion
Baseline olfactory dysfunction was not associated with motor deficits and complications, but it was associated with cognitive dysfunction and prognosis, suggesting that severe olfactory impairment may reflect early cortical involvement, probably in the frontotemporal region, and rapid spreading of Lewy body pathology.

Citations

Citations to this article as recorded by  
  • Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson’s disease
    Fardin Nabizadeh, Kasra Pirahesh, Elham Khalili
    Neurological Sciences.2022; 43(7): 4193.     CrossRef
  • Novel diagnostic tools for identifying cognitive impairment using olfactory-stimulated functional near-infrared spectroscopy: patient-level, single-group, diagnostic trial
    Jaewon Kim, Dong Keon Yon, Kyu Yeong Choi, Jang Jae Lee, Namwoo Kim, Kun Ho Lee, Jae Gwan Kim
    Alzheimer's Research & Therapy.2022;[Epub]     CrossRef
  • The Role of Olfactory System in the Etiogenesis of Parkinson’s Diseases: An Overview
    Jiju Narayanan Avanipully, Dithu Thekkekkara, Sahyadri M, Vipan K. Parihar, Santhepete Nanjundaiah Manjula
    Journal of Pharmacology and Pharmacotherapeutics.2022; 13(1): 31.     CrossRef
  • International consensus statement on allergy and rhinology: Olfaction
    Zara M. Patel, Eric H. Holbrook, Justin H. Turner, Nithin D. Adappa, Mark W. Albers, Aytug Altundag, Simone Appenzeller, Richard M. Costanzo, Ilona Croy, Greg E. Davis, Puya Dehgani‐Mobaraki, Richard L. Doty, Valerie B. Duffy, Bradley J. Goldstein, David
    International Forum of Allergy & Rhinology.2022; 12(4): 327.     CrossRef
  • Does Olfactory Dysfunction Correlate with Disease Progression in Parkinson’s Disease? A Systematic Review of the Current Literature
    Tommaso Ercoli, Carla Masala, Gianluca Cadeddu, Marcello Mario Mascia, Gianni Orofino, Angelo Fabio Gigante, Paolo Solla, Giovanni Defazio, Lorenzo Rocchi
    Brain Sciences.2022; 12(5): 513.     CrossRef
  • Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson’s disease
    Fardin Nabizadeh, Fatemeh Sodeifian, Kasra Pirahesh
    Neurological Sciences.2022; 43(8): 4745.     CrossRef
  • Olfaction and Executive Cognitive Performance: A Systematic Review
    Vasudeva Murthy Challakere Ramaswamy, Peter William Schofield
    Frontiers in Psychology.2022;[Epub]     CrossRef
  • Nasal and Parotid Blood Pool Activity Is Significantly Correlated with Metabolic Syndrome Components and Sleep Apnea
    William T. Phillips, Nasser J. Issa, Shereef B. Elhalwagi, Hilda T. Draeger, Joyce G. Schwartz, Jonathan A. Gelfond
    Metabolic Syndrome and Related Disorders.2022; 20(7): 395.     CrossRef
  • Chronic neuropsychiatric sequelae of SARS‐CoV‐2: Protocol and methods from the Alzheimer's Association Global Consortium
    Gabriel A. de Erausquin, Heather Snyder, Traolach S. Brugha, Sudha Seshadri, Maria Carrillo, Rajesh Sagar, Yueqin Huang, Charles Newton, Carmela Tartaglia, Charlotte Teunissen, Krister Håkanson, Rufus Akinyemi, Kameshwar Prasad, Giovanni D'Avossa, Gabriel
    Alzheimer's & Dementia: Translational Research & Clinical Interventions.2022;[Epub]     CrossRef
  • Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease
    Joshua Harvey, Rick A. Reijnders, Rachel Cavill, Annelien Duits, Sebastian Köhler, Lars Eijssen, Bart P. F. Rutten, Gemma Shireby, Ali Torkamani, Byron Creese, Albert F. G. Leentjens, Katie Lunnon, Ehsan Pishva
    npj Parkinson's Disease.2022;[Epub]     CrossRef
  • Impact of Subthalamic Deep Brain Stimulation on Hyposmia in Patients With Parkinson's Disease Is Influenced by Constipation and Dysbiosis of Microbiota
    Chao Li, Ying Hou, Xu Wang, Yue-xuan Li, Feng Li, Chao Zhang, Wei-guo Li
    Frontiers in Neurology.2021;[Epub]     CrossRef
  • Hyposmia may predict development of freezing of gait in Parkinson’s disease
    Jae Jung Lee, Jin Yong Hong, Jong Sam Baik
    Journal of Neural Transmission.2021; 128(6): 763.     CrossRef
  • Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson’s Disease
    Han Soo Yoo, Sangwon Lee, Seong Ho Jeong, Byoung Seok Ye, Young H. Sohn, Mijin Yun, Phil Hyu Lee
    Journal of Parkinson's Disease.2021; 11(4): 1703.     CrossRef
Review Articles
Progressive Supranuclear Palsy with Predominant Cerebellar Ataxia
Shoichiro Ando, Masato Kanazawa, Osamu Onodera
J Mov Disord. 2020;13(1):20-26.   Published online December 19, 2019
DOI: https://doi.org/10.14802/jmd.19061
  • 6,882 View
  • 354 Download
  • 12 Citations
AbstractAbstract PDF
Progressive supranuclear palsy (PSP) is characterized by supranuclear gaze palsy, dystonic rigidity of the neck and upper trunk, frequent falls and mild cognitive impairment. Cerebellar ataxia is one of the exclusion criteria given by the National Institute of Neurological Disorders and Stroke and the Society for Progressive Supranuclear Palsy. As a result, pathologically proven PSP patients exhibiting cerebellar ataxia have often been misdiagnosed with spinocerebellar degeneration, specifically multiple system atrophy with predominant cerebellar ataxia (MSA-C). However, more recently, it has been recognized that patients with PSP can present with truncal and limb ataxia as their initial symptom and/or main manifestation. These patients can be classified as having PSP with predominant cerebellar ataxia (PSP-C), a new subtype of PSP. Since the development of this classification, patients with PSP-C have been identified primarily in Asian countries, and it has been noted that this condition is very rare in Western communities. Furthermore, the clinical features of PSP-C have been identified, enabling it to be distinguished from other subtypes of PSP and MSA-C. In this review, we describe the clinical and neuropathological features of PSP-C. The hypothesized pathophysiology of cerebellar ataxia in PSP-C is also discussed.

Citations

Citations to this article as recorded by  
  • Deciphering the saccade velocity profile of progressive supranuclear palsy: A sign of latent cerebellar/brainstem dysfunction?
    Yasuo Terao, Shin-ichi Tokushige, Satomi Inomata-Terada, Hideki Fukuda, Akihiro Yugeta, Yoshikazu Ugawa
    Clinical Neurophysiology.2022; 141: 147.     CrossRef
  • Parkinsonism and ataxia
    Giulia Franco, Giulia Lazzeri, Alessio Di Fonzo
    Journal of the Neurological Sciences.2022; 433: 120020.     CrossRef
  • Differential Diagnosis of Rare Subtypes of Progressive Supranuclear Palsy and PSP-Like Syndromes—Infrequent Manifestations of the Most Common Form of Atypical Parkinsonism
    Patrycja Krzosek, Natalia Madetko, Anna Migda, Bartosz Migda, Dominika Jaguś, Piotr Alster
    Frontiers in Aging Neuroscience.2022;[Epub]     CrossRef
  • Clinical Aspects of the Differential Diagnosis of Parkinson’s Disease and Parkinsonism
    Hae-Won Shin, Sang-Wook Hong, Young Chul Youn
    Journal of Clinical Neurology.2022; 18(3): 259.     CrossRef
  • Clinical Spectrum of Tauopathies
    Nahid Olfati, Ali Shoeibi, Irene Litvan
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Toward More Accessible Fully Automated 3D Volumetric MRI Decision Trees for the Differential Diagnosis of Multiple System Atrophy, Related Disorders, and Age-Matched Healthy Subjects
    Jisoo Kim, Geoffrey S. Young, Andrew S. Willett, Ariana T. Pitaro, Grace F. Crotty, Merlyne Mesidor, Kristie A. Jones, Camden Bay, Min Zhang, Mel B. Feany, Xiaoyin Xu, Lei Qin, Vikram Khurana
    The Cerebellum.2022;[Epub]     CrossRef
  • The Role of the Cerebellum in Swallowing
    Ayodele Sasegbon, Shaheen Hamdy
    Dysphagia.2021;[Epub]     CrossRef
  • Cerebellar ataxia in progressive supranuclear palsy: a clinico-pathological case report
    David Crosiers, Anne Sieben, Sarah Ceyssens, Paul M. Parizel, Jonathan Baets
    Acta Neurologica Belgica.2021; 121(2): 599.     CrossRef
  • Progressive supranuclear palsy
    N.V. Fedorova, E.V. Bril, T.K. Kulua, A.D. Mikhaylova
    Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021; 121(5): 111.     CrossRef
  • Case 20-2021: A 69-Year-Old Man with Ataxia
    Richard C. Cabot, Eric S. Rosenberg, David M. Dudzinski, Meridale V. Baggett, Kathy M. Tran, Dennis C. Sgroi, Jo-Anne O. Shepard, Emily K. McDonald, Tara Corpuz, Vikram Khurana, Claudio M. de Gusmao, McKinley Glover, Jeffrey Helgager
    New England Journal of Medicine.2021; 385(2): 165.     CrossRef
  • Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies
    Maria Stamelou, Gesine Respondek, Nikolaos Giagkou, Jennifer L. Whitwell, Gabor G. Kovacs, Günter U. Höglinger
    Nature Reviews Neurology.2021; 17(10): 601.     CrossRef
  • Tauopathy and Movement Disorders—Unveiling the Chameleons and Mimics
    Jacky Ganguly, Mandar Jog
    Frontiers in Neurology.2020;[Epub]     CrossRef
Long-Term Outcomes of Genetic Parkinson’s Disease
Jan O. Aasly
J Mov Disord. 2020;13(2):81-96.   Published online May 29, 2020
DOI: https://doi.org/10.14802/jmd.19080
  • 10,195 View
  • 368 Download
  • 10 Citations
AbstractAbstract PDF
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects 1–2% of people by the age of 70 years. Age is the most important risk factor, and most cases are sporadic without any known environmental or genetic causes. Since the late 1990s, mutations in the genes SNCA, PRKN, LRRK2, PINK1, DJ-1, VPS35, and GBA have been shown to be important risk factors for PD. In addition, common variants with small effect sizes are now recognized to modulate the risk for PD. Most studies in genetic PD have focused on finding new genes, but few have studied the long-term outcome of patients with the specific genetic PD forms. Patients with known genetic PD have now been followed for more than 20 years, and we see that they may have distinct and different prognoses. New therapeutic possibilities are emerging based on the genetic cause underlying the disease. Future medication may be based on the pathophysiology individualized to the patient’s genetic background. The challenge is to find the biological consequences of different genetic variants. In this review, the clinical patterns and long-term prognoses of the most common genetic PD variants are presented.

Citations

Citations to this article as recorded by  
  • PTEN-Induced Putative Kinase 1 Dysfunction Accelerates Synucleinopathy
    Tinh Thi Nguyen, Yun Joong Kim, Thuy Thi Lai, Phuong Thi Nguyen, Young Ho Koh, Linh Thi Nhat Nguyen, Hyeo-il Ma, Young Eun Kim
    Journal of Parkinson's Disease.2022; 12(4): 1201.     CrossRef
  • Oncogenic Pathways in Neurodegenerative Diseases
    Luis Varela, Maria E. R. Garcia-Rendueles
    International Journal of Molecular Sciences.2022; 23(6): 3223.     CrossRef
  • Genetic Determinants of Survival in Parkinson's Disease in the Asian Population
    Chunyu Li, Yanbing Hou, Ruwei Ou, Xiaojing Gu, Yongping Chen, Lingyu Zhang, Kuncheng Liu, Junyu Lin, Bei Cao, Qianqian Wei, Xueping Chen, Wei Song, Bi Zhao, Ying Wu, Yiyuan Cui, Huifang Shang
    Movement Disorders.2022; 37(8): 1624.     CrossRef
  • Obituary for Jan O. Aasly (1950–2022)
    Matthew J. Farrer
    Movement Disorders.2022; 37(9): 1783.     CrossRef
  • Genetics in parkinson’s disease: From better disease understanding to machine learning based precision medicine
    Mohamed Aborageh, Peter Krawitz, Holger Fröhlich
    Frontiers in Molecular Medicine.2022;[Epub]     CrossRef
  • Recent developments in nucleic acid-based therapies for Parkinson’s disease: Current status, clinical potential, and future strategies
    Shivam Kumar Pandey, Rakesh Kumar Singh
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Genetic stratification of motor and QoL outcomes in Parkinson's disease in the EARLYSTIM study
    Daniel Weiss, Zied Landoulsi, Patrick May, Manu Sharma, Michael Schüpbach, Hana You, Jean Christophe Corvol, Steffen Paschen, Ann-Kristin Helmers, Michael Barbe, Gereon Fink, Andrea A. Kühn, Christine Brefel Courbon, Lars Wojtecki, Philippe Damier, Valeri
    Parkinsonism & Related Disorders.2022; 103: 169.     CrossRef
  • Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort
    Jan O. Aasly
    Frontiers in Neuroscience.2021;[Epub]     CrossRef
  • Increased Mortality in Young-Onset Parkinson’s Disease
    Eldbjørg Hustad, Tor Åge Myklebust, Sasha Gulati, Jan O. Aasly
    Journal of Movement Disorders.2021; 14(3): 214.     CrossRef
  • Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort
    Sylvia Binck, Claire Pauly, Michel Vaillant, Geraldine Hipp, Manon Gantenbein, Rejko Krueger, Nico J Diederich
    Frontiers in Neurology.2020;[Epub]     CrossRef
Original Articles
Comparison of Spontaneous Motor Tempo during Finger Tapping, Toe Tapping and Stepping on the Spot in People with and without Parkinson’s Disease
Dawn Rose, Daniel J. Cameron, Peter J. Lovatt, Jessica A. Grahn, Lucy E. Annett
J Mov Disord. 2020;13(1):47-56.   Published online January 31, 2020
DOI: https://doi.org/10.14802/jmd.19043
  • 12,264 View
  • 144 Download
  • 10 Citations
AbstractAbstract PDFSupplementary Material
Objective
Spontaneous motor tempo (SMT), observed in walking, tapping and clapping, tends to occur around 2 Hz. Initiating and controlling movement can be difficult for people with Parkinson’s (PWP), but studies have not identified whether PWP differ from controls in SMT. For community-based interventions, e.g. dancing, it would be helpful to know a baseline SMT to optimize the tempi of cued activities. Therefore, this study compared finger tapping (FT), toe tapping (TT) and stepping ‘on the spot’ (SS) in PWP and two groups of healthy controls [age-matched controls (AMC) and young healthy controls (YHC)], as SMT is known to change with age.
Methods
Participants (PWP; n = 30, AMC; n = 23, YHC; n = 35) were asked to tap or step on the spot at a natural pace for two trials lasting 40 seconds. The central 30 seconds were averaged for analyses using mean inter-onset intervals (IOI) and coefficient of variation (CoV) to measure rate and variability respectively.
Results
PWP had faster SMT than both control groups, depending on the movement modality: FT, F(2, 87) = 7.92, p < 0.01 (PWP faster than YHC); TT, F(2, 87) = 4.89, p = 0.01 (PWP faster than AMC); and SS, F(2, 77) = 3.26, p = 0.04 (PWP faster than AMC). PWP had higher CoV (more variable tapping) than AMC in FT only, F(2, 87) = 4.10, p = 0.02.
Conclusion
This study provides the first direct comparison of SMT between PWP and two control groups for different types of movements. Results suggest SMT is generally faster in PWP than control groups, and more variable when measured with finger tapping compared to stepping on the spot.

Citations

Citations to this article as recorded by  
  • Deficient Interhemispheric Connectivity Underlies Movement Irregularities in Parkinson’s Disease
    Manuel Bange, Gabriel Gonzalez-Escamilla, Tabea Marquardt, Angela Radetz, Christian Dresel, Damian Herz, Wolfgang Immanuel Schöllhorn, Sergiu Groppa, Muthuraman Muthuraman
    Journal of Parkinson's Disease.2022; 12(1): 381.     CrossRef
  • Memory-Paced Tapping to Auditory Rhythms: Effects of Rate, Speech, and Motor Engagement
    Anat Kliger Amrani, Elana Zion Golumbic
    Journal of Speech, Language, and Hearing Research.2022; 65(3): 923.     CrossRef
  • Virtual Reality to Evaluate the Impact of Colorful Interventions and Nature Elements on Spontaneous Walking, Gaze, and Emotion
    Adamantia Batistatou, Florentin Vandeville, Yvonne N. Delevoye-Turrell
    Frontiers in Virtual Reality.2022;[Epub]     CrossRef
  • Synchronization during Improvised Active Music Therapy in clients with Parkinson’s disease
    Demian Kogutek, Emily Ready, Jeffrey D. Holmes, Jessica A. Grahn
    Nordic Journal of Music Therapy.2022; : 1.     CrossRef
  • Neural synchronization is strongest to the spectral flux of slow music and depends on familiarity and beat salience
    Kristin Weineck, Olivia Xin Wen, Molly J Henry
    eLife.2022;[Epub]     CrossRef
  • Spontaneous motor tempo contributes to preferred music tempo regardless of music familiarity
    Kyoko Hine, Koki Abe, Yuya Kinzuka, Mohammad Shehata, Katsunobu Hatano, Toshie Matsui, Shigeki Nakauchi
    Frontiers in Psychology.2022;[Epub]     CrossRef
  • A general procedure to measure the pacing of body movements timed to music and metronome in younger and older adults
    Dawn Rose, Laurent Ott, Ségolène M. R. Guérin, Lucy E. Annett, Peter Lovatt, Yvonne N. Delevoye-Turrell
    Scientific Reports.2021;[Epub]     CrossRef
  • Synchronization and locking in oscillators with flexible periods
    Mariya Savinov, David Swigon, Bard Ermentrout
    Chaos: An Interdisciplinary Journal of Nonlinear Science.2021; 31(3): 033143.     CrossRef
  • Hierarchical control as a shared neurocognitive mechanism for language and music
    Rie Asano, Cedric Boeckx, Uwe Seifert
    Cognition.2021; 216: 104847.     CrossRef
  • Spontaneous and stimulus-driven rhythmic behaviors in ADHD adults and controls
    Anat Kliger Amrani, Elana Zion Golumbic
    Neuropsychologia.2020; 146: 107544.     CrossRef
Automated Brainstem Segmentation Detects Differential Involvement in Atypical Parkinsonian Syndromes
Martina Bocchetta, Juan Eugenio Iglesias, Viorica Chelban, Edwin Jabbari, Ruth Lamb, Lucy L. Russell, Caroline V. Greaves, Mollie Neason, David M. Cash, David L. Thomas, Jason D. Warren, John Woodside, Henry Houlden, Huw R. Morris, Jonathan D. Rohrer
J Mov Disord. 2020;13(1):39-46.   Published online September 26, 2019
DOI: https://doi.org/10.14802/jmd.19030
  • 4,992 View
  • 213 Download
  • 10 Citations
AbstractAbstract PDFSupplementary Material
Objective
Brainstem segmentation has been useful in identifying potential imaging biomarkers for diagnosis and progression in atypical parkinsonian syndromes (APS). However, the majority of work has been performed using manual segmentation, which is time consuming for large cohorts.
Methods
We investigated brainstem involvement in APS using an automated method. We measured the volume of the medulla, pons, superior cerebellar peduncle (SCP) and midbrain from T1-weighted MRIs in 67 patients and 42 controls. Diagnoses were corticobasal syndrome (CBS, n = 14), multiple system atrophy (MSA, n = 16: 8 with parkinsonian syndrome, MSA-P; 8 with cerebellar syndrome, MSA-C), progressive supranuclear palsy with a Richardson’s syndrome (PSP-RS, n = 12), variant PSP (n = 18), and APS not otherwise specified (APS-NOS, n = 7).
Results
All brainstem regions were smaller in MSA-C (19–42% volume difference, p < 0.0005) and in both PSP groups (18–33%, p < 0.0005) than in controls. MSA-P showed lower volumes in all regions except the SCP (15–26%, p < 0.0005). The most affected region in MSA-C and MSA-P was the pons (42% and 26%, respectively), while the most affected regions in both the PSP-RS and variant PSP groups were the SCP (33% and 23%, respectively) and midbrain (26% and 24%, respectively). The brainstem was less affected in CBS, but nonetheless, the pons (14%, p < 0.0005), midbrain (14%, p < 0.0005) and medulla (10%, p = 0.001) were significantly smaller in CBS than in controls. The brainstem was unaffected in APS-NOS.
Conclusion
Automated methods can accurately quantify the involvement of brainstem structures in APS. This will be important in future trials with large patient numbers where manual segmentation is unfeasible.

Citations

Citations to this article as recorded by  
  • Neuroimaging correlates of brain injury in Wilson’s disease: a multimodal, whole-brain MRI study
    Samuel Shribman, Martina Bocchetta, Carole H Sudre, Julio Acosta-Cabronero, Maggie Burrows, Paul Cook, David L Thomas, Godfrey T Gillett, Emmanuel A Tsochatzis, Oliver Bandmann, Jonathan D Rohrer, Thomas T Warner
    Brain.2022; 145(1): 263.     CrossRef
  • Nuclear imaging in Parkinson's disease: The past, the present, and the future
    Haim Golan, Olga Volkov, Eli Shalom
    Journal of the Neurological Sciences.2022; 436: 120220.     CrossRef
  • Criteria-unfulfilled multiple system atrophy at an initial stage exhibits laterality of middle cerebellar peduncles
    Minori Furuta, Masayuki Sato, Setsuki Tsukagoshi, Yoshito Tsushima, Yoshio Ikeda
    Journal of the Neurological Sciences.2022; 438: 120281.     CrossRef
  • A data-driven model of brain volume changes in progressive supranuclear palsy
    W. J. Scotton, M. Bocchetta, E. Todd, D. M. Cash, N. Oxtoby, L. VandeVrede, H. Heuer, D. C. Alexander, J. B. Rowe, H. R. Morris, A. Boxer, J. D. Rohrer, P. A. Wijeratne
    Brain Communications.2022;[Epub]     CrossRef
  • Neuroimaging Correlates of Cognitive Deficits in Wilson's Disease
    Samuel Shribman, Maggie Burrows, Rhian Convery, Martina Bocchetta, Carole H. Sudre, Julio Acosta‐Cabronero, David L. Thomas, Godfrey T. Gillett, Emmanuel A. Tsochatzis, Oliver Bandmann, Jonathan D. Rohrer, Thomas T. Warner
    Movement Disorders.2022; 37(8): 1728.     CrossRef
  • Corticobasal syndrome and Parkinson’s disease at the beginning: asymmetrical patterns of MRI and Blink Reflex for early diagnosis
    Giulia Donzuso, Giorgia Sciacca, Antonina Luca, Calogero E. Cicero, Giovanni Mostile, Alessandra Nicoletti, Mario Zappia
    Journal of Neural Transmission.2022; 129(12): 1427.     CrossRef
  • Eye movements and association with regional brain atrophy in clinical subtypes of progressive supranuclear palsy
    Ji-Hyun Choi, Heejung Kim, Jung Hwan Shin, Jee-Young Lee, Han-Joon Kim, Jong-Min Kim, Beomseok Jeon
    Journal of Neurology.2021; 268(3): 967.     CrossRef
  • Artificial intelligence applied to neuroimaging data in Parkinsonian syndromes: Actuality and expectations
    Annalisa Vitale, Rossella Villa, Lorenzo Ugga, Valeria Romeo, Arnaldo Stanzione, Renato Cuocolo
    Mathematical Biosciences and Engineering.2021; 18(2): 1753.     CrossRef
  • Differential early subcortical involvement in genetic FTD within the GENFI cohort
    Martina Bocchetta, Emily G. Todd, Georgia Peakman, David M. Cash, Rhian S. Convery, Lucy L. Russell, David L. Thomas, Juan Eugenio Iglesias, John C. van Swieten, Lize C. Jiskoot, Harro Seelaar, Barbara Borroni, Daniela Galimberti, Raquel Sanchez-Valle, Ro
    NeuroImage: Clinical.2021; 30: 102646.     CrossRef
  • Quantitative MRI markers in Parkinson's disease and parkinsonian syndromes
    Germain Arribarat, Patrice Péran
    Current Opinion in Neurology.2020; 33(2): 222.     CrossRef
Review Article
Manganese and Movement Disorders: A Review
Dinkar Kulshreshtha, Jacky Ganguly, Mandar Jog
J Mov Disord. 2021;14(2):93-102.   Published online April 6, 2021
DOI: https://doi.org/10.14802/jmd.20123
  • 5,933 View
  • 366 Download
  • 9 Citations
AbstractAbstract PDF
Scientific and technological advances achieved with industrial expansion have led to an ever-increasing demand for heavy metals. This demand has, in turn, led to increased contamination of soil, water and air with these metals. Chronic exposure to metals may be detrimental not only to occupational workers but also to the nonoccupational population exposed to these metals. Manganese (Mn), a commonly used heavy metal, is an essential cofactor for many enzymatic processes that drive biological functions. However, it is also a potential source of neurotoxicity, particularly in the field of movement disorders. The typical manifestation of Mn overexposure is parkinsonism, which may be difficult to differentiate from the more common idiopathic Parkinson’s disease. In addition to environmental exposure to Mn, other potential etiologies causing hypermanganesemia include systemic health conditions, total parenteral nutrition and genetic mutations causing Mn dyshomeostasis. In this review, we critically analyze Mn and discuss its sources of exposure, pathophysiology and clinical manifestations. We have highlighted the global public health impact of Mn and emphasize that movement disorder specialists should record a detailed social and occupational history to ensure that a toxic etiology is not misdiagnosed as a neurodegenerative disease. In the absence of a definite therapeutic option, early diagnosis and timely institution of preventive measures are the keys to managing its toxic effects.

Citations

Citations to this article as recorded by  
  • Differentiating Wild and Apiary Honey by Elemental Profiling: a Case Study from Mangroves of Indian Sundarban
    Tanushree Gaine, Praveen Tudu, Somdeep Ghosh, Shouvik Mahanty, Madhurima Bakshi, Nabanita Naskar, Souparna Chakrabarty, Subarna Bhattacharya, Swati Gupta Bhattacharya, Kashinath Bhattacharya, Punarbasu Chaudhuri
    Biological Trace Element Research.2022; 200(10): 4550.     CrossRef
  • Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson’s Disease Pathogenesis: A Narrative Review
    Efthalia Angelopoulou, Yam Nath Paudel, Sokratis G. Papageorgiou, Christina Piperi
    Brain Sciences.2022; 12(2): 175.     CrossRef
  • Ayahuasca as a Decoction Applied to Human: Analytical Methods, Pharmacology and Potential Toxic Effects
    Ľuboš Nižnanský, Žofia Nižnanská, Roman Kuruc, Andrea Szórádová, Ján Šikuta, Anežka Zummerová
    Journal of Clinical Medicine.2022; 11(4): 1147.     CrossRef
  • Can therapeutic plasma exchange be life-saving in life-threatening manganese intoxication?
    Emel Uyar, Esra Gurkas, Aysel Unlusoy Aksu, Serhat Emeksiz, Cigdem Seher Kasapkara, Nadide Basak Gulleroglu, Ikbal Ok Bozkaya, Kader Karlı Oguz
    Transfusion and Apheresis Science.2022; 61(4): 103417.     CrossRef
  • Manganese‐induced parkinsonism responsive to intranasal insulin: A case report
    Mehri Salari, Masoud Etemadifar, Leila Dargahi, Neda Valian, Malihe Rezaee
    Clinical Case Reports.2022;[Epub]     CrossRef
  • The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson’s disease
    Adrianne F. Pike, Ildikò Szabò, Robert Veerhuis, Luigi Bubacco
    npj Parkinson's Disease.2022;[Epub]     CrossRef
  • Effect of Chelation Therapy on a Korean Patient With Brain Manganese Deposition Resulting From a Compound Heterozygous Mutation in the SLC39A14 Gene
    Jae-Hyeok Lee, Jin-Hong Shin
    Journal of Movement Disorders.2022; 15(2): 171.     CrossRef
  • Manganese chloride (MnCl2) induced novel model of Parkinson’s disease in adult Zebrafish; Involvement of oxidative stress, neuroinflammation and apoptosis pathway
    Abhishek.P.R. Nadig, Bader Huwaimel, Ahmed Alobaida, El-Sayed Khafagy, Hadil Faris Alotaibi, Afrasim Moin, Amr Selim Abu Lila, Suman, Sahyadri. M, K.L. Krishna
    Biomedicine & Pharmacotherapy.2022; 155: 113697.     CrossRef
  • Çalışma Yaşamında Manganez Maruz Kalımının Sağlık Etkileri ve Parkinsonizm
    Zehra GÖK METİN, Abdulsamet SANDAL, Ali Naci YILDIZ
    Karaelmas İş Sağlığı ve Güvenliği Dergisi.2021; 5(2): 147.     CrossRef
Letter to the editor
Chorea as a Presentation of SARS-CoV-2 Encephalitis: A Clinical Case Report
Muhammad Hassan, Fibhaa Syed, Liaqat Ali, Haris Majid Rajput, Farhan Faisal, Waleed Shahzad, Mazhar Badshah
J Mov Disord. 2021;14(3):245-247.   Published online March 15, 2021
DOI: https://doi.org/10.14802/jmd.20098
  • 5,522 View
  • 159 Download
  • 8 Citations
PDFSupplementary Material

Citations

Citations to this article as recorded by  
  • Relationship between COVID‐19 and movement disorders: A narrative review
    Susanne A. Schneider, Anita Hennig, Davide Martino
    European Journal of Neurology.2022; 29(4): 1243.     CrossRef
  • Comment on “Chorea as a Presentation of SARS-CoV-2 Encephalitis: A Clinical Case Report”
    Ruth H. Walker
    Journal of Movement Disorders.2022; 15(1): 93.     CrossRef
  • Re: Comments on “Chorea as a Presentation of SARS-CoV-2 Encephalitis: A Clinical Case Report”
    Muhammad Hassan, Naveed Ullah Khan, Mazhar Badshah
    Journal of Movement Disorders.2022; 15(1): 94.     CrossRef
  • Encephalitis in Patients with COVID-19: A Systematic Evidence-Based Analysis
    Md Asiful Islam, Cinzia Cavestro, Sayeda Sadia Alam, Shoumik Kundu, Mohammad Amjad Kamal, Faruque Reza
    Cells.2022; 11(16): 2575.     CrossRef
  • Chorea as a Post‐COVID ‐19 Complication
    Farzad Ashrafi, Mehri Salari, Fatemeh Hojjati Pour
    Movement Disorders Clinical Practice.2022;[Epub]     CrossRef
  • Neurological manifestations in COVID-19: how relevant is this association?
    Manuela DE MICHELE, Irene BERTO, Luca PETRAGLIA, Oscar G. SCHIAVO, Federica MORET, Ettore NICOLINI, Nicoletta CARACCIOLO, Maria Teresa DI MASCIO, Danilo TONI
    Italian Journal of Emergency Medicine.2021;[Epub]     CrossRef
  • Sars‐Cov ‐2 in a Patient with Acute Chorea: Innocent Bystander or Unexpected Actor?
    Matteo Cotta Ramusino, Giulia Perini, Gabriele Corrao, Lisa Farina, Giulia Berzero, Mauro Ceroni, Alfredo Costa
    Movement Disorders Clinical Practice.2021; 8(6): 950.     CrossRef
  • Neurological complications of SARS-CoV-2: A single-center case series authors
    Muhammad Hassan, Naveed Ullah Khan, Mansoor Iqbal, Zakir Jan, Haris Majid Rajput, Rebecca Susan Dewey, Mazhar Badshah
    Brain Hemorrhages.2021; 2(4): 161.     CrossRef

JMD : Journal of Movement Disorders